drugset / Trial / NCT03240809
An Open-label, Single-dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Brodalumab in Pediatric Subjects
Non-randomizedParallel-groupOpen-labelTreatment
Summary
An Open-label, Single-dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Brodalumab in Pediatric Subjects
Timeline
- Start
- 2020-01-24
- Primary completion
- 2028-12
- Completion
- 2029-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Brodalumab | Monoclonal antibody | 70 mg | Subcutaneous |
| Subject | Brodalumab | Monoclonal antibody | 140 mg | Subcutaneous |